These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22731403)

  • 1. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
    Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
    J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of silent information regulator 1 (Sirt1) agonists from Traditional Chinese Medicine.
    Chen KC; Jian YR; Sun MF; Chang TT; Lee CC; Chen CY
    J Biomol Struct Dyn; 2013; 31(11):1207-18. PubMed ID: 23075283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
    Maltarollo VG; Honório KM
    Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
    J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
    Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
    J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
    Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
    PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
    Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
    PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
    Nath V; Agrawal R; Kumar V
    J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
    Fracchiolla G; Laghezza A; Piemontese L; Parente M; Lavecchia A; Pochetti G; Montanari R; Di Giovanni C; Carbonara G; Tortorella P; Novellino E; Loiodice F
    Bioorg Med Chem; 2012 Mar; 20(6):2141-51. PubMed ID: 22341573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
    Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
    Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-α (PPAR-α) agonists.
    Gangwal RP; Damre MV; Das NR; Sharma SS; Sangamwar AT
    Bioorg Med Chem Lett; 2015 Jan; 25(2):270-5. PubMed ID: 25491112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
    Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
    Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations.
    Feng XY; Jia WQ; Liu X; Jing Z; Liu YY; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():178-189. PubMed ID: 30557816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators.
    Molnár F; Matilainen M; Carlberg C
    J Biol Chem; 2005 Jul; 280(28):26543-56. PubMed ID: 15888456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring molecular fingerprints of selective PPARδ agonists through comparative and validated chemometric techniques.
    Nandy A; Roy K; Saha A
    SAR QSAR Environ Res; 2015; 26(5):363-82. PubMed ID: 25986170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.